Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI

L. Thorsson, S. Edsbäcker, T-B. Conradson

ABSTRACT: The pulmonary and systemic availability of budesonide after inhalation from a dry powder inhaler, Turbuhaler®, and from a pressurized metered-dose inhaler (P-MDI) were compared in healthy volunteers.

Two different methods were used to assess pulmonary availability: 1) calculated from the systemic availability corrected for an oral availability of 13% (n=24); and 2) after blocking of gastrointestinal absorption by administration of a charcoal suspension (n=13). An intravenous infusion of budesonide was used as a reference.

The systemic availability of budesonide, calculated as a geometric mean and expressed as percentage of the metered dose, was 38% for Turbuhaler® and 26% for P-MDI. The pulmonary availability, calculated using the first method, was 32% and 15% for Turbuhaler® and P-MDI, respectively; and, using the second method, 32% and 18%, respectively.

The results of the present study indicate that administration of budesonide via Turbuhaler® gives rise to a lung deposition which is approximately twice that of a P-MDI, with less variability, but that systemic availability is only increased by approximately 50%. Thus, the present data suggest that by administrating budesonide via Turbuhaler®, instead of a P-MDI, the same degree of asthma control can be achieved with a lower dose, which, in turn, reduces the risk of undesired systemic effects.
yr) and mean body weight 68 kg (range 45–92 kg). All subjects were healthy, as judged by routine physical examination, including haematology, blood chemistry tests and urinalysis. All subjects were moderate consumers of alcohol and nonsmokers, with the exception of one subject who occasionally smoked cigarettes. The study was approved by the Ethics Committee of the University of Lund and by the Medical Product Agency, Uppsala, Sweden. The trial was performed in accordance with the Declaration of Helsinki. The subjects were informed about the study, verbally and in writing, and gave their written consent to participation.

Methods

Two different methods were used to assess pulmonary availability: 1) in 24 healthy subjects, it was calculated from the systemic availability corrected for an assumed oral availability of 13%; and 2) in 13 of the subjects, it was determined directly after blocking of gastrointestinal absorption by concomitant administration of a charcoal suspension.

All 24 subjects received an intravenous administration of budesonide as a reference, and all 24 were studied over design. The administration of oral budesonide, with concomitant charcoal suspension, was performed in a nonrandomized manner at the end of the study. The samples from one of these 14 subjects were lost and, thus, data from only 13 subjects could be completely evaluated.

The study was of an open, partially randomized, cross-over design. The administration of oral budesonide, with concomitant charcoal suspension, was performed in a nonrandomized manner at the end of the study. The following single doses and formulations of budesonide (nominal doses) were administered, with intervals of at least 8 weeks between two consecutive study days: 1 mg (5×200 µg) via Turbuhaler® and via P-MDI. Fifteen of the 24 subjects inhaled budesonide via Turbuhaler® and via P-MDI after oral administration of an activated charcoal suspension. Fourteen of these 15 subjects also received an oral administration of budesonide (micronized powder in a capsule) with concomitant activated charcoal. This latter treatment was performed in order to permit a compensation to be made, in the availability calculations, for a small fraction of drug still being absorbed from the GI tract. The samples from one of these 14 subjects were lost and, thus, data from only 13 subjects could be completely evaluated.

The inspiratory flow and volume of each inhalation for Turbuhaler® and from P-MDI were recorded using a pulmonary function analyser (Vitalograph® Compact, Vitalograph Ltd, UK) with a specially designed interface. The subjects were trained to breathe out to residual volume, and then to inhale at a flow of 60 l/min for Turbuhaler®, and 30 l/min for P-MDI; and, for the latter, to actuate the dose, with the mouth closed around the adapter, during inhalation. After inhalation, the breath was held for 5 s before a slow exhalation was performed through a Respirgard® filter. The subject then breathed gently through the filter until the next dose was administered. A noseclip was used to prevent nose-breathing. A total nominal dose of 1 mg was administered in five doses of 200 µg, taken at intervals of 40 s. The Turbuhaler® inhalers were primed by removing five doses by vacuum suction, using a separate mouthpiece, before use by the subject. The P-MDI was primed, prior to the study administration, by actuating five doses into a plastic bag, using a separate adapter. The Turbuhaler® inhalers and the P-MDIs were individually characterized with regard to drug output. The metered-dose was calculated as a mean of the doses leaving the dose reservoirs (standard in vitro measurement using a mean of five doses from Turbuhaler® and a mean of 10 doses from P-MDI). The amount of drug retained in the mouthpiece/adapter and exhalation filters was determined by thorough rinsing with ethanol (99.5%) containing an internal standard, and subsequent liquid chromatography.

The intravenous dose was administered as an infusion over 9 min into an antecubital vein of the arm not used for blood sampling. The dose was estimated by weighing the syringe before and after infusion. The oral dose, administered as micronized powder in a gelatine capsule, was specified by weighing the amount of budesonide powder put into each capsule. Blood samples were obtained from an indwelling catheter inserted into an antecubital vein. The plasma was separated by centrifugation (1,500 G) for 10 min and was then immediately frozen at -20°C until analysed. The assay of budesonide in plasma was based on a combination of liquid chromatography and mass spectrometry (LC-MS) [8].

Pharmacokinetic parameters were calculated according to routine methods. The systemic availability was calculated as the ratio of inhalation to intravenous area under the plasma concentration versus time curve (AUC). The individual systemic availability data were log-transformed and means were expressed as geometric means with 95% confidence limits. A pairwise comparison of the treatments was performed using a multiplicative statistical model. For all other parameters, means are expressed as arithmetic means.
Pulmonary availability: method with assumed GI availability

The amount of budesonide deposited in and absorbed from the lung ($F_{lung}$) was calculated from the systemic availability ($F_{sys}$), assuming an oral availability ($F_{oral}$) of 13%, using the equation:

$$F_{lung} = \frac{F_{sys} \cdot F_{oral} (1 - ret)}{1 - F_{oral}}$$

where "ret" is the fraction of the metered dose retained in the device and exhaled onto the filters. The oral availability of 13% was obtained in a previous in-house study, in which 11 healthy subjects received an intravenous administration of budesonide (0.5 mg) and an oral administration of budesonide (4 mg in gelatine capsules). The value of 13% is the highest mean value which has been found for the oral availability of budesonide, and was used in the present study in order to estimate the highest possible GI contribution to the systemic availability. In previously published studies, the oral availability of budesonide has been estimated to be 6% [9] and 11% [10].

Pulmonary availability: charcoal-block method

Pulmonary availability was determined in 13 of the subjects who were given charcoal suspensions in conjunction with budesonide administrations. In order to obtain pulmonary availability data, the systemic availability values were adjusted individually for drug absorbed from the GI tract. The GI tract absorption data were obtained from the oral administration of budesonide with concomitant charcoal suspension.

Results

Analysis of individual Turbuhaler® devices revealed that, of the nominal dose of 1,000 µg (5×200 µg), a mean (±SD) of 891±83 µg left the dose reservoir (metered dose), 191±45 µg was retained in the mouthpiece, and 0–14 µg (range) was exhaled. Corresponding figures for individual P-MDI were 935±69 µg (metered dose), 72±33 µg retained in the adapter, and 0–15 µg exhaled.

The inhalations were performed under controlled conditions. The flows (mean±SD) were 52±13 l/min⁻¹ for Turbuhaler® and 40±19 l/min⁻¹ for P-MDI administrations, 0.5 s after the start of the inhalation, and 48±14 l/min⁻¹ and 29±8 l/min⁻¹, respectively, after 3.0 s. The inhaled volumes were 3.2±0.7 l for Turbuhaler® and 2.5±1.1 l for the P-MDI administrations.

No budesonide was detected in any of the plasma samples taken immediately before each administration.

Systemic availability

Figure 1 shows the mean plasma concentrations after intravenous dosing and after dosing via inhalation with Turbuhaler® and P-MDI, without charcoal. The peak budesonide plasma concentration (Cmax) was higher after inhalation via Turbuhaler®, 3.5 nmol·l⁻¹ (range 2.2–5.6 nmol·l⁻¹) attained at 0.3 h (range 0.2–0.7 h), than for the P-MDI, 2.3 nmol·l⁻¹ (range 0.7–4.0 nmol·l⁻¹) attained at 0.5 h (range 0.2–3.0 h). The Turbuhaler® to P-MDI Cmax quotient was estimated to be 1.7 (95% confidence limits (CL) 1.4–2.0). Mean absorption time was 1.0 h (range 0.3–1.8 h) for Turbuhaler® and 1.4 h (range 0.8–2.6 h) for the P-MDI.

After inhalation via Turbuhaler®, 38% (geometric mean, range 23–62%) of the metered-dose was systemically available, and after inhalation via P-MDI, the value was 26% (geometric mean, range 15–53%). The Turbuhaler® to P-MDI systemic availability quotient was estimated to be 1.5 (95% CL 1.3–1.7).

From intravenous data, the plasma half-life of budesonide was calculated as 2.3 h (range 1.7–3.4 h). The plasma concentration curves entered the terminal phase between 1 and 3 h. Plasma clearance and volume of distribution (Vss) were 1.34 l·kg⁻¹ (range 1.41–5.02 l·kg⁻¹), respectively. From the amount of drug absorbed from the lung and the contribution, to the systemic circulation, of drug absorbed via the GI tract was presented graphically in figure 2. From the amount of drug entering the systemic circulation via the GI tract, it can be calculated that this fraction (6/38 for Turbuhaler® and 11/26 for P-MDI) is about 2.7 times higher after inhalation via Turbuhaler® than after inhalation via P-MDI.

Pulmonary availability: method with assumed GI availability

The pulmonary availability, calculated relative to metered-doses and assuming an oral availability of 13%, was 32% (geometric mean, range 16–59%) for Turbuhaler® and 15% (range 3–47%) for P-MDI. The Turbuhaler® to P-MDI pulmonary availability quotient was estimated to be 2.2 (95% CL 1.6–2.9). The amount of drug absorbed from the lung and the contribution, to the systemic circulation, of drug absorbed via the GI tract is presented graphically in figure 2. From the amount of drug entering the systemic circulation via the GI tract, it can be calculated that this fraction (6/38 for Turbuhaler® and 11/26 for P-MDI) is about 2.7 times higher after inhalation via P-MDI than after inhalation via Turbuhaler®.

The variability of the pulmonary availability, relative to the metered-dose, was significantly lower (p=0.0006) for Turbuhaler®, with a coefficient of variation (CV) of 32.8% as compared with a CV of 76.7% for P-MDI.
Pulmonary availability: charcoal-block method

Plasma concentrations of budesonide, in the 13 subjects who received all three administrations (P-MDI, Turbuhaler® and oral capsule) with concomitant charcoal suspension are illustrated in figure 3. With respect to Cmax and Tmax, the plasma budesonide profiles are virtually identical, regardless of the concomitant use of charcoal suspension. The oral availability of budesonide, after concomitant charcoal administration, was found to be 2.5%. With an oral availability of 13% without charcoal, the preventive effect of charcoal on budesonide absorption can be estimated to be approximately 80%. The pulmonary availability, calculated using the metered doses from Turbuhaler® and P-MDI, with concomitant administration of charcoal, and compensated for the contribution of orally absorbed drug, was 32% for Turbuhaler® and 18% for the P-MDI. The Turbuhaler® to P-MDI pulmonary availability quotient was estimated to be 1.8 (95% CL 1.3–2.5).

Discussion

In this study, the pulmonary and systemic availability of budesonide after inhalation from a dry powder inhaler, Turbuhaler®, and from a P-MDI were compared. The pulmonary availability was 32% for Turbuhaler® and 15% for P-MDI (assuming an oral availability of 13%). The systemic availability of budesonide was 38% from Turbuhaler®, and 26% from P-MDI. In a gamma-scintigraphic study on lung deposition of 99mTc-labelled budesonide via Turbuhaler®, 27.7% of the metered dose was deposited in the lungs at a peak inspiratory flow of 58 l/min [11]. Similar results were obtained in the present study, irrespective of the method used for calculating pulmonary availability.

The pulmonary availability for Turbuhaler® was about twice that for the P-MDI. The systemic availability of the metered dose of budesonide after inhalation via Turbuhaler® is about 50% higher than that seen after inhalation via the P-MDI. However, with Turbuhaler®, a significantly larger fraction, 2.2 times (95% CL 1.6–2.9),...
of the metered-dose was deposited in the lungs than with P-MDI. The contribution from pulmonary absorbed drug to the overall systemic availability (lung/total = L/T ratio), calculated for all 24 subjects using the administratons without charcoal and an oral availability of 13%, was 84% for Turbuhaler® and 58% for the P-MDI.

Metabolic inactivation in the lung has not been demonstrated for any of the inhaled glucocorticosteroids currently available. Thus, when a glucocorticostero is inhaled into the lungs, systemic absorption of the drug is inevitable. As a consequence of an increased lung deposition of the drug, not only an increased pulmonary effect, but also an increased systemic absorption should occur. However, an increased lung deposition is accompanied by a reduced oropharyngeal deposition, i.e. a reduction in the fraction of the dose which is systemically available via the GI tract, and which does not contribute to the local effect in the lung. Since budesonide via Turbuhaler®, has a high first-pass metabolism and can be administered via an inhalation system which gives a high degree of lung deposition, the GI contribution to the systemic availability of budesonide is negligible.

The relationship between P-MDI and Turbuhaler® obtained in the present study is in agreement with a previous clinical study in asthmatic children, in which budesonide via Turbuhaler® was found to be equally effective as twice the dose from a P-MDI with a large volume spacer [6]. Holding chambers and spacers are used to decrease the oropharyngeal deposition from a P-MDI, in order to avoid local side-effects such as hoarseness and oropharyngeal candidiasis. In a recent study in 154 patients using a steroid P-MDI with spacer, the frequency of local side-effects, mainly hoarseness, was reduced from 21 to 6% when transferring from P-MDI to budesonide via Turbuhaler® [12].

It cannot be ruled out that a less strict and less well-controlled inhalation procedure, than that used in the present study, could have resulted in a difference between Turbuhaler® and P-MDI which would have been even more accentuated. An inhalation flow of 60 l/min is clinically relevant for Turbuhaler® as most asthmatic patients have no difficulties, in general, in reaching this flow [13]. In acute asthma, 98% of the patients were able to generate a peak inspiratory flow (PIF) of >30 l/min through Turbuhaler® (mean±SD 60±20 l/min), which permits efficient use of the inhaler [14]. Virtually all children aged ≥6 yrs, and about 75% of children <6 yrs, were able to generate a PIF of ≥28 l/min through Turbuhaler®, and should, thus, benefit from budesonide administered via Turbuhaler® [15]. The inhalation flow of 30 l/min for the P-MDI was chosen in order to optimize the lung deposition [16].

The variability (coefficient of variation) for the in vitro measurement of the metered dose was 7% for P-MDI (935±69 µg) and 10% for Turbuhaler® (891±83 µg). The in vivo results for pulmonary availability were vice versa, with a variability for Turbuhaler® which was significantly lower (approximately twice) than that of the P-MDI. This difference between in vitro and in vivo results is probably due to the fact that the relatively small variability seen under standardized in vitro conditions becomes less important when the biological variation e.g. of inhalation technique, is added. In the present study, the inhalation technique was carefully monitored, thus minimizing variability. In clinical practice, the variabiility may be anticipated to be even larger.

In conclusion, the results of the present study indicate that administration of budesonide via Turbuhaler® gives rise to a lung deposition which is approximately twice that of a P-MDI, with less variability. Despite the doubled lung deposition from Turbuhaler®, systemic availability is only increased by approximately 50%, as compared with a P-MDI. Thus these data suggest that by administrating budesonide via Turbuhaler®, instead of a P-MDI, the same degree of asthma control can be achieved with a lower dose, which, in turn, further reduces the risk of undesired systemic effects.

Acknowledgement: The authors wish to thank A. Blomqvist for analysing budesonide in the plasma samples.

References
11. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder


